SCHEMBL24089953

SCHEMBL24089953

O=c1c2cc(F)cc(F)c2nc(Nc2ccccc2)n1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A2 O94788 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALDH1A3 P47895 1/20 0.39
GLA P06280 1/20 0.38
MAT2A P31153 1/20 0.38
MAPK1 P28482 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24111001 0.90 PIK3CD (0.41) MAPTALDH1A2ALDH1A1ALDH1A3
SCHEMBL30103287 0.90 PIK3CD (0.41) MAPTALDH1A2ALDH1A1ALDH1A3
SCHEMBL23064664 0.89 ALDH1A1 (0.39) USP2MAPTALDH1A2ALDH1A1ALDH1A3
SCHEMBL24090085 0.86 ALDH1A1 (0.42) USP2MAPTALDH1A2ALDH1A1ALDH1A3
SCHEMBL29623155 0.83 TDO2 (0.50) USP2MAPTMAT2A
SCHEMBL23045334 0.83 TDO2 (0.50) USP2MAPTMAT2A
SCHEMBL23958353 0.78 TRPV4 (0.40) MAPTALDH1A2ALDH1A1ALDH1A3MAT2A
SCHEMBL23958176 0.78 ALPL (0.39) USP2MAPTALDH1A2ALDH1A1ALDH1A3
SCHEMBL23958194 0.77 TDO2 (0.46) USP2MAPTMAT2A
SCHEMBL23958201 0.76 ALOX12 (0.43) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 CN claimed
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 CN disclosed
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL USP2 3443/4885MAPT 4827/4885ALDH1A2 623/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 USP2 3548/4885MAPT 4783/4885ALDH1A2 547/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 USP2 3548/4885MAPT 4783/4885ALDH1A2 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.